Cargando…

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma

With the advent of new targeted drugs in hematology and oncology patient prognosis is improved. Combination with antifungal prophylaxis challenges clinicians due to pharmacological profiles prone to drug–drug interactions (DDI). Midostaurin is a novel agent for FLT3-TKD/-ITD(mut)-acute myeloid leuke...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stemler, Jannik, Koehler, Philipp, Maurer, Christian, Müller, Carsten, Cornely, Oliver A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316674/ https://www.ncbi.nlm.nih.gov/pubmed/32514626 http://dx.doi.org/10.1007/s00277-020-04107-1

Ejemplares similares

P586: POTENTIAL DRUG-DRUG INTERACTIONS OF ANTIFUNGAL PROPHYLAXIS AND MIDOSTAURIN IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA – CLINICAL IMPLICATIONS OF THERAPEUTIC DRUG MONITORING
por: Joisten, Carolin, et al.
Publicado: (2023)

Antifungal Prophylaxis in Acute Myeloid Leukemia: New Drugs, New Challenges?: Summary of the EHA Guideline on Antifungal Prophylaxis in Adult Patients With Acute Myeloid Leukemia Treated With Novel-targeted Therapies
por: Stemler, Jannik, et al.
Publicado: (2022)

The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study
por: Özkocaman, Vildan, et al.
Publicado: (2018)

Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study
por: Menna, Pierantonio, et al.
Publicado: (2023)

Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia
por: Tu, Songji, et al.
Publicado: (2023)

Rhabdomyolysis Following Initiation of Posaconazole Use for Antifungal Prophylaxis in a Patient With Relapsed Acute Myeloid Leukemia: A Case Report
por: Mody, Mayur D., et al.
Publicado: (2017)

Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
por: Döring, M., et al.
Publicado: (2015)

Midostaurin: an emerging treatment for acute myeloid leukemia patients
por: Gallogly, Molly Megan, et al.
Publicado: (2016)

P487: MIDOSTAURIN PLASMA EXPOSURE IN PATIENTS WITH FLT3-MUT ACUTE MYELOID LEUKEMIA UNDERGOING POSACONAZOLE PROPHYLAXIS DURING INDUCTION TREATMENT: A PROSPECTIVE MULTICENTRE STUDY FROM THE SEIFEM GROUP
por: Marchesi, Francesco, et al.
Publicado: (2023)

Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia
por: Gutierrez, Lucas, et al.
Publicado: (2018)

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation
por: Döring, Michaela, et al.
Publicado: (2012)

Economic analysis of oral posaconazole prophylaxis in acute myeloid leukemia during remission induction in Turkey
por: Umit, Elif Gulsum, et al.
Publicado: (2020)

Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents
por: Kang, Ka-Won, et al.
Publicado: (2020)

Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection
por: Abbas, Hussein A, et al.
Publicado: (2019)

Posaconazole for the prophylaxis of invasive aspergillosis in acute myeloid leukemia: Is it still useful outside the clinical trial setting?
por: Chen, Tsung-Chih, et al.
Publicado: (2020)

Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020)

Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain
por: Arenaza, Ainhoa, et al.
Publicado: (2019)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

412. Clinical and Pharmacoeconomic Evaluation of Antifungal Prophylaxis With Continuous Micafungin Compared to Posaconazole With Micafungin Bridging in Patients Undergoing Allogeneic Stem Cell Transplantation: A 6-Year Cohort Analysis
por: Heimann, Sebastian M, et al.
Publicado: (2018)

Correction Notice: Antifungal Prophylaxis in Acute Myeloid Leukemia: New Drugs, New Challenges? Summary of the EHA Guideline on Antifungal Prophylaxis in Adult Patients With Acute Myeloid Leukemia Treated With Novel-targeted Therapies
Publicado: (2022)

Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis
por: Kang, Seung Hun, et al.
Publicado: (2015)

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
por: Döring, M., et al.
Publicado: (2013)

Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia
por: Garitano-Trojaola, Andoni, et al.
Publicado: (2021)

Midostaurin as the Most Likely Cause of Bilateral Adrenal Masses in a Patient with Acute Myeloid Leukemia
por: Schutte, Tim, et al.
Publicado: (2022)

PB1790: ABCB1 AS A POTENTIAL BENEFICIAL TARGET OF MIDOSTAURIN IN ACUTE MYELOID LEUKEMIA
por: Sucha, S., et al.
Publicado: (2022)

Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia
por: Lee, Julia S., et al.
Publicado: (2023)

Factors Influencing the Safety and Efficiency of Antifungal Prophylaxis with Posaconazole in Children with Hematological Diseases: From Genetics to Polypharmacotherapy
por: Sienkiewicz-Oleszkiewicz, Beata, et al.
Publicado: (2019)

Effectiveness of Posaconazole in Recalcitrant Fungal Keratitis Resistant to Conventional Antifungal Drugs
por: Altun, A., et al.
Publicado: (2014)

Dendrimer-based posaconazole nanoplatform for antifungal therapy
por: Tang, Shengzhuang, et al.
Publicado: (2021)

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
por: De Gregori, Simona, et al.
Publicado: (2023)

2119. Matched-Paired Analysis of Patients Treated for Invasive Mucormycosis—Standard Treatment vs. Posaconazole New Formulations (MoveOn)
por: Salmanton-Garcia, Jon, et al.
Publicado: (2019)

Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients
por: Rosenberg, Mara W., et al.
Publicado: (2020)

Midostaurin-Related Interstitial Lung Injury in FLT3(+) Acute Myeloid Leukemia Post-Allogeneic Transplant
por: Vaidya, Poorva, et al.
Publicado: (2019)

Isavuconazole Therapy of Disseminated and Encephalic Saprochaete Capitata Infection in an Acute Myeloid Leukemia Patient Treated with Midostaurin
por: Perrone, Salvatore, et al.
Publicado: (2020)

Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology–oncology patients: a retrospective cohort study
por: Kung, Hsiang-Chi, et al.
Publicado: (2014)

Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study
por: Ye, Peipei, et al.
Publicado: (2022)

2731. Posa-bly the Better Option? Comparison of Posaconazole vs. Itraconazole for Antifungal Prophylaxis After Heart Transplantation
por: Drucker, Darra, et al.
Publicado: (2023)

Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis
por: Calmettes, Claire, et al.
Publicado: (2018)

Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis – Authors' reply
por: Koehler, Philipp, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4t9m46jgus7n8qiilusl1mcnd9